Evaluate the Efficacy and Safety of Proso Millet and Wheat Extract(Keranat™) on Hair Health

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-02

Study Completion Date

2023-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this randomized, double-blind, placebo-controlled study will be to evaluate whether the daily intake of Keranat™ for 24 weeks can promote the gloss and elasticity of hairs, improve their density and strength, and reduce hair loss.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating the Effects of Dietary Supplement on Hair Thickness and Hair Strength in Individuals With Self-Perceived Thinning Hair

NCT06605768

Hair Thinning

COMPLETED NA

Effectiveness of a Novel Dietary Ingredient on Hair Growth and Skin's Appearance

NCT06010745

Hair Thinning Facial Skin Texture Skin Ageing

UNKNOWN NA

Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment

NCT07348120

Telogen Effluvium

ACTIVE_NOT_RECRUITING NA

Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men

NCT06362941

Hair Thinning

COMPLETED NA

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

NCT07041489

Hair Thinning

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hair Damage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Keranat™

Keranat™ capsule will be administered orally twice daily for 24 weeks.

Group Type EXPERIMENTAL

Keranat™

Intervention Type DIETARY_SUPPLEMENT

300 mg/capsule(proso millet and wheat extract 600 mg/day)

Placebo

Placebo capsule will be administered orally twice daily for 24 weeks.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DIETARY_SUPPLEMENT

300 mg/capsule(600 mg/day as placebo)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Keranat™

300 mg/capsule(proso millet and wheat extract 600 mg/day)

Intervention Type DIETARY_SUPPLEMENT

placebo

300 mg/capsule(600 mg/day as placebo)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 19 and 60
* Hair gloss score of 3 or less and a hair damage score of less than 18 according to the visual evaluation classification method.
* Willing to maintain the same hairstyle, hair color, hair length, and hair regimen throughout the study period.
* Subject must be able to comprehend and voluntarily sign study procedures and consent forms.

Exclusion Criteria

* Those diagnosed with and receiving treatment for the alopecia within 3 months before screening(androgenetic alopecia, alopecia areata, Telogen effluvium, etc.)
* Use of that may affect hair or hair loss symptoms treatment medicine, dietary supplements, or treatments containing herbal medicine ingredients within 3 months before screening.
* Any active scalp or skin disease that may interfere with the study treatment and evaluations.
* Pregnancy or breastfeeding or planning pregnancy
* Case of abnormal values at creatinine (excess at the upper limit of the reference range)
* Case of abnormal values at ALT or AST (2 times excess at the upper limit of the reference range)

Minimum Eligible Age

19 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes